Abstract
Objective For more than a century, developing novel and effective vaccines against malaria and tuberculosis (TB) infections has been a challenge. This review sought to investigate the reasons for the slow progress of malaria and TB vaccine candidates in sub-Saharan African clinical trials.
Methods The systematic review protocol was registered on PROSPERO on July 26, 2023 (CRD42023445166). The research articles related to the immunogenicity, efficacy, or safety of malaria or TB vaccines that were published between January 1, 2012, and August 31, 2023, were searched on three databases: Web of Science (WoS), PubMed, and ClinicalTrials.gov.
Results A total of 2342 articles were obtained, 50 of which met the inclusion criteria. 28 (56%) articles reported on malaria vaccine attributes, while 22 (44%) articles reported on TB vaccines. In both cases, the major challenges in sub-Saharan African clinical trials were immunogenicity and efficacy, rather than safety.
Conclusion Factors such as population characteristics, pathogen genetic diversity, vaccine nature, strategy, and formulation were associated with slow progress of the malaria and TB vaccine candidates in sub-Saharan African clinical trials.
Author summary Vaccines are one of the most powerful control strategies for both infectious and non-infectious diseases. The lack of durable vaccines and the development of antimicrobial resistance have made malaria and TB threats to human lives, specifically in sub-Saharan Africa. The search for novel, reliable, and durable vaccines against these infections has been underway for more than a decade. Despite this, none have resulted in vaccines with all three preferred critical attributes: immunogenicity, efficacy, and safety. This indicates that there are hindering challenges that have been neglected in the development pipeline. This review focused on understanding these challenges in sub-Saharan African clinical trials. The results of the study are crucial for the identification of areas for improvement in vaccine design, evaluation, and implementation strategies, hence driving advancements in NTD vaccine research and development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Strategic Research Fund (SRF), Ministry of Science, Technology, and Innovation (MOSTI), Malaysia, Grant number: 305.PPSK.614503.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
